Lapisteride
From Wikipedia, the free encyclopedia
 | |
|---|---|
| Systematic (IUPAC) name | |
| N-[1-(4-methoxyphenyl)-1-methylethyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide | |
| Clinical data | |
| Legal status | Non-regulated |
| Routes | Oral[1] |
| Identifiers | |
| CAS number | 142139-60-4  |
| ATC code | None |
| PubChem | CID 9847295 |
| ChemSpider | 8023009 |
| UNII | T50SJ23G82 |
| Chemical data | |
| Formula | C29H40N2O3 |
| Mol. mass | 464.6395 g/mol |
| SMILES
| |
| |
| (what is this?) (verify) | |
Lapisteride (INN; CS-891) is a dual inhibitor of both isoforms of the enzyme 5α-reductase.[2] It was under investigation for the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia,[2][3] but was never marketed.
See also
- 5α-reductase inhibitor
References
- ↑ Yada S, Ohya M, Ohuchi Y, et al. (April 2003). "Solid phase transition of CS-891 enantiotropes during grinding". International Journal of Pharmaceutics 255 (1-2): 69–79. doi:10.1016/S0378-5173(03)00084-X. PMID 12672603.
- ↑ 2.0 2.1 Niiyama S, Kojima K, Hamada T, Happle R, Hoffmann R (December 2000). "The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles". European Journal of Dermatology 10 (8): 593–5. PMID 11125319.
- ↑ Bernan; British Pharmacopoeia Commission (February 2002). British Approved Names 2002. The Stationery Office. p. 157. ISBN 978-0-11-322558-3. Retrieved 17 November 2011.
| |||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.